Eli Lilly's (LLY) Kisunla Gets FDA Approval for Safer Alzheimer's Dosing Schedule

Eli Lilly & Company (NYSE:LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company (NYSE:LLY)’s Alzheimer’s therapy Kisunla received approval from the US Food and Drug Administration on July 9 for a label update that included a new recommended titration dose schedule.

When compared to the initial dose plan, the adjusted donanemab-azbt titration schedule substantially lowered the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E). The updated schedule maintained comparable levels of amyloid plaque removal while reducing ARIA-E rates by 41% at 24 weeks and 35% at 52 weeks.

The FDA first authorized Kisunla back in July 2024 based on evidence from the TRAILBLAZER-ALZ 2 Phase 3 clinical trial, which showed the medication reduced cognitive and functional deterioration in people with early-stage Alzheimer’s.

Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes an assortment of medications. Founded in 1876, it has evolved into one of the world’s largest pharmaceutical companies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.